EURAX (crotamiton) by Journey Medical is clinical pharmacology: pruradik lotion has scabicial and antipruritic actions. First approved in 1955.
Drug data last refreshed 4h ago · AI intelligence enriched 3w ago
EURAX (crotamiton) is a topical lotion with scabicial and antipruritic actions approved in 1955 for the treatment of scabies and pruritus. The exact mechanism of action remains unknown, though clinical efficacy is well-established. It is applied directly to affected skin areas.
Product approaching loss of exclusivity with moderate competitive pressure (30/100), suggesting a contracting team and focus on cost management and generic preparation strategies.
CLINICAL PHARMACOLOGY: Pruradik lotion has scabicial and antipruritic actions. The mechanisms of these actions are not known. The pharmacokinetics of crotamiton and its degree of systemic absorption following topical application have not been determined.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Neuraxial Ultrasound Device Study
Teaching Neuraxial Ultrasonography With a Virtual Reality Simulator of Spine
PENG Block vs FNB + ONB in Patients Undergoing Hip Fracture Surgery With Contraindications to Neuraxial Anesthesia
A Study to Test Performance of Needle Placements for Neuraxial Procedures Using Tactile Imaging vs Control
The Effect of a Culturally Sensitive Educational Intervention on Acceptance of Neuraxial Anesthesia
Worked on EURAX at Journey Medical? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
With zero linked job openings and an LOE-approaching lifecycle, EURAX offers limited growth career opportunities. Roles on this product focus on defensive strategies, cost containment, and managed transition to post-patent competition.